Hong Kong Stock Innovative Drug Concept Continues Rally, Akeso Surges Over 4%

Like
Comment
Favorite

Hong Kong Stock Innovative Drug Concept Continues Rally, Akeso Surges Over 4%

Deep News01-23

On January 23, the innovative drug concept in Hong Kong stocks continued its upward trajectory.

Everest Medicines surged over 7%, while XtalPi Holdings and Akeso rose more than 4%. Kelun-Biotech Biopharmaceutical, Ascentage Pharma, and 3SBio increased over 3%. Ascletis Pharma and Innovent Biologics gained more than 2%.

On individual stock news, according to an announcement on Akeso's official WeChat account, the company recently declared that the new drug application for its self-developed novel humanized anti-IL-17A monoclonal antibody, Gumokimab (AK111), intended for the treatment of active ankylosing spondylitis, has been accepted by the Center for Drug Evaluation of the National Medical Products Administration. This milestone indicates the drug has the potential to offer a new treatment alternative for nearly 4 million AS patients in China.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

Most Discussed

7x24

All

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1142659698?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-23 10:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142659698","market":"us","top_or_hot":-1,"title":"Hong Kong Stock Innovative Drug Concept Continues Rally, Akeso Surges Over 4%","media":"Deep News","content":"<p>On January 23, the innovative drug concept in Hong Kong stocks continued its upward trajectory.</p>\n<p>Everest Medicines surged over 7%, while XtalPi Holdings and Akeso rose more than 4%. Kelun-Biotech Biopharmaceutical, Ascentage Pharma, and 3SBio increased over 3%. Ascletis Pharma and Innovent Biologics gained more than 2%.</p>\n<p>On individual stock news, according to an announcement on Akeso's official WeChat account, the company recently declared that the new drug application for its self-developed novel humanized anti-IL-17A monoclonal antibody, Gumokimab (AK111), intended for the treatment of active ankylosing spondylitis, has been accepted by the Center for Drug Evaluation of the National Medical Products Administration. This milestone indicates the drug has the potential to offer a new treatment alternative for nearly 4 million AS patients in China.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Innovative Drug Concept Continues Rally, Akeso Surges Over 4%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Innovative Drug Concept Continues Rally, Akeso Surges Over 4%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-01-23 10:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On January 23, the innovative drug concept in Hong Kong stocks continued its upward trajectory.</p>\n<p>Everest Medicines surged over 7%, while XtalPi Holdings and Akeso rose more than 4%. Kelun-Biotech Biopharmaceutical, Ascentage Pharma, and 3SBio increased over 3%. Ascletis Pharma and Innovent Biologics gained more than 2%.</p>\n<p>On individual stock news, according to an announcement on Akeso's official WeChat account, the company recently declared that the new drug application for its self-developed novel humanized anti-IL-17A monoclonal antibody, Gumokimab (AK111), intended for the treatment of active ankylosing spondylitis, has been accepted by the Center for Drug Evaluation of the National Medical Products Administration. This milestone indicates the drug has the potential to offer a new treatment alternative for nearly 4 million AS patients in China.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1794554557.SGD","symbol_name":"Allianz All China Equity AT Acc H2-SGD","start_time":0,"source_url":"","article_id":"1142659698","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142659698","pubTimestamp":1769135501,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"On January 23, the innovative drug concept in Hong Kong stocks continued its upward trajectory. Everest Medicines surged over 7%, while XtalPi Holdings and Akeso rose more than 4%. Kelun-Biotech...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU0561508036.HKD":"ALLIANZ CHINA EQUITY \"A\" (HKD) INC","LU2476274720.SGD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC","BK1574":"生物医药B类股","09926":"康方生物","LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","06978":"永泰生物-B","LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","LU2399975544.HKD":"ALLIANZ ALL CHINA EQUITY \"AT\" (HKD) ACC","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","LU0348827113.USD":"ALLIANZ RCM CHINA \"AT\" ACC","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","LU1720050803.USD":"安联全方位中国股票基金","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","02800":"盈富基金","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","LU1961090484.USD":"ALLIANZ ALL CHINA EQUITY \"A\" (USD) INC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC","BK1161":"生物科技","LU0348783233.USD":"安联东方收入型 CI A Dis美元","BK1610":"ETF&股票定投概念","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC"},"translate_title":"港股创新药概念延续涨势康方生物大涨超4%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"02800":1,"06978":1,"09926":1},"content_text":"On January 23, the innovative drug concept in Hong Kong stocks continued its upward trajectory.\nEverest Medicines surged over 7%, while XtalPi Holdings and Akeso rose more than 4%. Kelun-Biotech Biopharmaceutical, Ascentage Pharma, and 3SBio increased over 3%. Ascletis Pharma and Innovent Biologics gained more than 2%.\nOn individual stock news, according to an announcement on Akeso's official WeChat account, the company recently declared that the new drug application for its self-developed novel humanized anti-IL-17A monoclonal antibody, Gumokimab (AK111), intended for the treatment of active ankylosing spondylitis, has been accepted by the Center for Drug Evaluation of the National Medical Products Administration. This milestone indicates the drug has the potential to offer a new treatment alternative for nearly 4 million AS patients in China.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}